70,423 results match your criteria Alzheimers Research & Therapy[Journal]


Preparation and Characterization of Curcumin-Loaded Polymeric Nanomicelles to Interference with Amyloidogenesis through Glycation Method.

Biotechnol Appl Biochem 2019 Apr 16. Epub 2019 Apr 16.

Bioengineering Research Group, Nanotechnology and Advanced Materials Department, Materials and Energy Research Center (MERC), P.O. Box 14155-4777, Tehran, Iran.

Amyloid fibrils, including β-amyloid (Aβ) fibrils, are protein aggregates that form under certain conditions, associated with neurodegeneration that interfere with neural synaptic transmission resulting in some neural disorders, such as Alzheimer disease. The aim of this study is to inhibit amyloidogenesis by using preparatory polymeric nanomicelles as therapeutic agents and also as nano carriers for curcumin to target Aβ fibrils through the glycation method of Bovine Serum Albumin (BSA) in the presence of Phosphate Buffer Saline (PBS). Polymeric nanomicelles were prepared from Phosphatidylethanolamine-distearoyl methoxypolyethylene glycol conjugates in the presence and absence of Curcumin and then the morphological and structural characteristics of the nanomicelles were characterized in detail. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1002/bab.1751
Publisher Site
http://dx.doi.org/10.1002/bab.1751DOI Listing
April 2019
1 Read

Biological Hallmarks of Cancer in Alzheimer's Disease.

Mol Neurobiol 2019 Apr 16. Epub 2019 Apr 16.

Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, IN, USA.

Although Alzheimer's disease (AD) is an international health research priority for our aging population, little therapeutic progress has been made. This lack of progress may be partially attributable to disease heterogeneity. Previous studies have identified an inverse association of cancer and AD, suggesting that cancer history may be one source of AD heterogeneity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12035-019-1591-5DOI Listing

eBrain: a Three Dimensional Simulation Tool to Study Drug Delivery in the Brain.

Authors:
Yaki Setty

Sci Rep 2019 Apr 16;9(1):6162. Epub 2019 Apr 16.

Gateway Institute for Brain Research, 3321 College Avenue, Davie, 33314, Florida, USA.

Neurodegenerative disorders such as Alzheimer's and Parkinson's disease are severe disorders with acute symptoms that gradually progress. In the course of developing disease-modifying treatments for neurodegenerative disorders there is a need to develop novel strategies to increase efficacy of drugs and accelerate the development process. We developed a tool for simulating drug delivery in the brain by translating MRI data into an interactive 3D model. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-019-42261-3DOI Listing

APOE-ε4 risk variant for Alzheimer's disease modifies the association between cognitive performance and cerebral morphology in healthy middle-aged individuals.

Neuroimage Clin 2019 Apr 8;23:101818. Epub 2019 Apr 8.

Barcelonaβeta Brain Research Center, Pasqual Maragall Foundation, Barcelona, Spain; Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Madrid, Spain; Universitat Pompeu Fabra, Barcelona, Spain. Electronic address:

The APOE-ε4 genotype is the highest genetic risk factor for Alzheimer's disease (AD). In cognitively unimpaired individuals, it has been related to altered brain morphology, function and earlier amyloid beta accumulation. However, its impact on cognitive performance is less evident. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.nicl.2019.101818DOI Listing

Peri-Infarct Upregulation of the Oxytocin Receptor in Vascular Dementia.

J Neuropathol Exp Neurol 2019 May;78(5):436-452

Department of Translational Science and Molecular Medicine, Michigan State University, Grand Rapids, Michigan.

Vascular dementia (VaD) is cognitive decline linked to reduced cerebral blood perfusion, yet there are few therapeutic options to protect cognitive function following cerebrovascular accidents. The purpose of this study was to profile gene expression changes unique to VaD to identify and characterize disease relevant changes that could offer clues for future therapeutic direction. Microarray-based profiling and validation studies of postmortem frontal cortex samples from VaD, Alzheimer disease, and age-matched control subjects revealed that the oxytocin receptor (OXTR) was strongly and differentially upregulated in VaD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnen/nlz023DOI Listing

Amyloid-β Oligomers Regulate ADAM10 Synaptic Localization Through Aberrant Plasticity Phenomena.

Mol Neurobiol 2019 Apr 13. Epub 2019 Apr 13.

Department of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, Via Balzaretti 9, 20133, Milan, Italy.

A disintegrin and metalloproteinase 10 (ADAM10) is a synaptic enzyme that has been previously shown to limit amyloid-β (Aβ) peptide formation in Alzheimer's disease (AD). Furthermore, ADAM10 participates to spine shaping through the cleavage of adhesion molecules and its activity is under the control of synaptic plasticity events. In particular, long-term depression (LTD) promotes ADAM10 synaptic localization triggering its forward trafficking to the synapse, while long-term potentiation elicits ADAM10 internalization. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s12035-019-1583-5
Publisher Site
http://dx.doi.org/10.1007/s12035-019-1583-5DOI Listing
April 2019
1 Read

Reduction of aluminum ion neurotoxicity through a small peptide application - NAP treatment of Alzheimer's disease.

J Food Drug Anal 2019 Apr 12;27(2):551-564. Epub 2019 Jan 12.

Center for Infectious Disease and Cancer Research, Kaohsiung Medical University, Kaohsiung 807, Taiwan; Research Center for Environmental Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan; Department of Medical Imaging and Radiological Sciences, Kaohsiung Medical University, Kaohsiung 807, Taiwan; Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan; Institute of Medical Science and Technology, National Sun Yat-sen University, Kaohsiung 804, Taiwan; Department of Medical Research, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan. Electronic address:

Alzheimer's disease (AD) is the most common cause of dementia in late life. It is difficult to precisely diagnose AD at early stages, making biomarker search essential for further developments. The objective of this study was to identify protein biomarkers associated with aluminum ions toxicity (AD-like toxicity) in a human neuroblastoma cell model, SH-SY5Y and assess potential prevention by NAP (NAPVSIPQ). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jfda.2018.11.009DOI Listing
April 2019
2 Reads
0.395 Impact Factor

Personalized risk for clinical progression in cognitively normal subjects-the ABIDE project.

Alzheimers Res Ther 2019 Apr 16;11(1):33. Epub 2019 Apr 16.

Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.

Background: Biomarkers such as cerebrospinal fluid (CSF) and magnetic resonance imaging (MRI) have predictive value for progression to dementia in patients with mild cognitive impairment (MCI). The pre-dementia stage takes far longer, and the interpretation of biomarker findings is particular relevant for individuals who present at a memory clinic, but are deemed cognitively normal. The objective of the current study is to construct biomarker-based prognostic models for personalized risk of clinical progression in cognitively normal individuals presenting at a memory clinic. Read More

View Article

Download full-text PDF

Source
https://alzres.biomedcentral.com/articles/10.1186/s13195-019
Publisher Site
http://dx.doi.org/10.1186/s13195-019-0487-yDOI Listing
April 2019
1 Read

Intravenous Immunoglobulin for Patients With Alzheimer's Disease: A Systematic Review and Meta-Analysis.

Am J Alzheimers Dis Other Demen 2019 Apr 15:1533317519843720. Epub 2019 Apr 15.

1 Clinical Research and Evidence-Based Medicine Unit, Second Medical Department, Aristotle University of Thessaloniki, Hippokration General Hospital, Thessaloniki, Greece.

Aim: To assess the efficacy and safety of intravenous immunoglobulin (IVIg) for patients with Alzheimer's disease (AD).

Materials And Methods: We searched electronic databases and other sources for randomized controlled trials comparing IVIg with placebo or other treatment for adults with AD. Primary outcome was change from baseline in Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1533317519843720DOI Listing

No synergistic effect of subtherapeutic doses of donepezil and EVP-6124 in healthy elderly subjects in a scopolamine challenge model.

Alzheimers Dement (N Y) 2019 1;5:89-98. Epub 2019 Apr 1.

Centre for Human Drug Research, Leiden, the Netherlands.

Introduction: Donepezil is a widely used cholinesterase inhibitor in the management of Alzheimer's disease. Despite large-scaled evidence for its efficacy, elevated peripheral ACh levels often lead to side effects and are dose limiting. The present exploratory study is designed to determine the potentiation of the effects of donepezil by cotreatment with EVP-6124, an alpha-7 nicotinic agonist, to reduce scopolamine-induced cognitive deficits in healthy elderly subjects. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.trci.2019.02.002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6446049PMC

Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System.

Alzheimers Dement (Amst) 2019 Dec 2;11:301-309. Epub 2019 Apr 2.

Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom.

Introduction: Therapeutic strategies targeting protein aggregations are ready for clinical trials in atypical parkinsonian disorders. Therefore, there is an urgent need for neuroimaging biomarkers to help with the early detection of neurodegenerative processes, the early differentiation of the underlying pathology, and the objective assessment of disease progression. However, there currently is not yet a consensus in the field on how to describe utility of biomarkers for clinical trials in atypical parkinsonian disorders. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.dadm.2019.01.011DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6446052PMC
December 2019

Preanalytical sample handling recommendations for Alzheimer's disease plasma biomarkers.

Alzheimers Dement (Amst) 2019 Dec 2;11:291-300. Epub 2019 Apr 2.

Research and Development, Roche Diagnostics GmbH, Penzberg, Germany.

Introduction: We examined the influence of common preanalytical factors on the measurement of Alzheimer's disease-specific biomarkers in human plasma.

Methods: Amyloid β peptides (Aβ[1-40], Aβ[1-42]) and total Tau plasma concentrations were quantified using fully automated Roche Elecsys assays.

Results: Aβ(1-40), Aβ(1-42), and total Tau plasma concentrations were not affected by up to three freeze/thaw cycles, up to five tube transfers, the collection tube material, or the size; circadian rhythm had a minor effect. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.dadm.2019.02.002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6446057PMC
December 2019

No association between Parkinson disease and autoantibodies against NMDA-type glutamate receptors.

Transl Neurodegener 2019 3;8:11. Epub 2019 Apr 3.

1Department of Neurology, University Hospital Schleswig Holstein, Arnold-Heller Str. 3, 24105 Kiel, Germany.

Background: IgG-class autoantibodies to N-Methyl-D-Aspartate (NMDA)-type glutamate receptors define a novel entity of autoimmune encephalitis. Studies examining the prevalence of NMDA IgA/IgM antibodies in patients with Parkinson disease with/without dementia produced conflicting results. We measured NMDA antibodies in a large, well phenotyped sample of Parkinson patients without and with cognitive impairment ( = 296) and controls ( = 295) free of neuropsychiatric disease. Read More

View Article

Download full-text PDF

Source
https://translationalneurodegeneration.biomedcentral.com/art
Publisher Site
http://dx.doi.org/10.1186/s40035-019-0153-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6446289PMC
April 2019
1 Read

Biomarker-Drug and Liquid Biopsy Co-development for Disease Staging and Targeted Therapy: Cornerstones for Alzheimer's Precision Medicine and Pharmacology.

Front Pharmacol 2019 29;10:310. Epub 2019 Mar 29.

AXA Research Fund & Sorbonne University Chair, Paris, France.

Systems biology studies have demonstrated that different (epi)genetic and pathophysiological alterations may be mapped onto a single tumor's clinical phenotype thereby revealing commonalities shared by cancers with divergent phenotypes. The success of this approach in cancer based on analyses of traditional and emerging body fluid-based biomarkers has given rise to the concept of liquid biopsy enabling a non-invasive and widely accessible precision medicine approach and a significant paradigm shift in the management of cancer. Serial liquid biopsies offer clues about the evolution of cancer in individual patients across disease stages enabling the application of individualized genetically and biologically guided therapies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fphar.2019.00310DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6450260PMC

Dehydroepiandrosterone and Dehydroepiandrosterone Sulfate in Alzheimer's Disease: A Systematic Review and Meta-Analysis.

Front Aging Neurosci 2019 29;11:61. Epub 2019 Mar 29.

Department of Epidemiology and Health Statistics, Xiangya School of Public Health, Central South University, Changsha, China.

Previous studies found inconsistent results for the relationship between Alzheimer's disease and the levels of dehydroepiandrosterone and dehydroepiandrosterone sulfate. This study performed a systematic review and meta-analysis to evaluate previous studies' results on this relationship. Studies related to this outcome were obtained using a systematic search from the electronic databases of PubMed, Embase, Web of Science, and Psyc-ARTICLES in March 2018. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fnagi.2019.00061DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6449476PMC
March 2019
1 Read

Trajectories of the Hippocampal Subfields Atrophy in the Alzheimer's Disease: A Structural Imaging Study.

Front Neuroinform 2019 22;13:13. Epub 2019 Mar 22.

Department of Neurology, Xuanwu Hospital of Capital Medical University, Beijing, China.

Background: The hippocampus and hippocampal subfields have been found to be diversely affected in Alzheimer's Disease (AD) and early stages of Alzheimer's disease by neuroimaging studies. However, our knowledge is still lacking about the trajectories of the hippocampus and hippocampal subfields atrophy with the progression of Alzheimer's disease.

Objective: To identify which subfields of the hippocampus differ in the trajectories of Alzheimer's disease by magnetic resonance imaging (MRI) and to determine whether individual differences on memory could be explained by structural volumes of hippocampal subfields. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fninf.2019.00013DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6450438PMC
March 2019
1 Read

MIC-MAC: An automated pipeline for high-throughput characterization and classification of three-dimensional microglia morphologies in mouse and human postmortem brain samples.

Glia 2019 Apr 14. Epub 2019 Apr 14.

Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Belval, Luxembourg.

The phenotypic changes of microglia in brain diseases are particularly diverse and their role in disease progression, beneficial, or detrimental, is still elusive. High-throughput molecular approaches such as single-cell RNA-sequencing can now resolve the high heterogeneity in microglia population for a specific physiological condition, however, the relation between the different microglial signatures and their surrounding brain microenvironment is barely understood. Thus, better tools to characterize the phenotypic variations of microglia in situ are needed, particularly for human brain postmortem samples analysis. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1002/glia.23623
Publisher Site
http://dx.doi.org/10.1002/glia.23623DOI Listing
April 2019
4 Reads

M1 Muscarinic Receptor Activation Rescues β-Amyloid-Induced Cognitive Impairment through AMPA Receptor GluA1 Subunit.

Neuroscience 2019 Apr 11. Epub 2019 Apr 11.

Department of Pharmacology and Chemical Biology, Institute of Medical Sciences, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China. Electronic address:

M1 muscarinic receptors have long been identified as a potential therapeutic target for the treatment of cognitive impairment in Alzheimer's disease (AD). Our previous study has shown that M1 receptors promote membrane insertion and synaptic delivery of AMPA receptor GluA1 subunit. In this study, we sought to determine whether activation of M1 receptor would rescue the cognitive impairment in AD model mice through modulation of GluA1 subunit. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S03064522193024
Publisher Site
http://dx.doi.org/10.1016/j.neuroscience.2019.04.007DOI Listing
April 2019
2 Reads

Differences in cortical perfusion detected by arterial spin labeling in nonamnestic and amnestic subtypes of early-onset Alzheimer's disease.

J Neuroradiol 2019 Apr 11. Epub 2019 Apr 11.

U1171. In-vivo Imaging Platform, Predictive Medicine and Therapeutic Research Institute, Université Lille Nord de France, Lille, France; Department of Neuroradiology, CHU Lille, Lille, France.

Objectives: Early-onset Alzheimer's disease (EOAD) begins before the age of 65 and is characterized by a faster clinical course and the frequency of nonamnestic symptoms compared to late onset Alzheimer disease (LOAD). However, the pathophysiological process of EOAD remains unclear. We expected that ASL may show widespread cortical hypoperfusion in EOAD compared to LOAD and in nonamnestic EOAD compared to amnestic EOAD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neurad.2019.03.017DOI Listing

Exercise as a potential modulator of inflammation in patients with Alzheimer's disease measured in cerebrospinal fluid and plasma.

Exp Gerontol 2019 Apr 10. Epub 2019 Apr 10.

Danish Dementia Research Centre, Department of Neurology, Rigshospitalet University of Copenhagen, DK-2100 Copenhagen, Denmark. Electronic address:

Background: Neuroinflammation is recognized as part of the pathological progression of Alzheimer's disease (AD), but the molecular mechanisms are still not entirely clear. Systemically, physical exercise has shown to have a positive modulating effect on markers of inflammation. It is not known if this general effect also takes place in the central nervous system in AD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.exger.2019.04.003DOI Listing

C9orf72 hexanucleotide repeat length in older population: normal variation and effects on cognition.

Neurobiol Aging 2019 Mar 11. Epub 2019 Mar 11.

Molecular Neurology, Research Programs Unit, Department of Neurology, University of Helsinki, Helsinki University Hospital, Helsinki, Finland.

The hexanucleotide repeat expansion in C9orf72 is a common cause of amyotrophic lateral sclerosis/frontotemporal dementia and also rarely found in other psychiatric and neurodegenerative conditions. Alleles with >30 repeats are often considered an expansion, but the pathogenic repeat length threshold is still unclear. It is also unclear whether intermediate repeat length alleles (often defined either as 7-30 or 20-30 repeats) have clinically significant effects. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neurobiolaging.2019.02.026DOI Listing

CSF glial biomarkers YKL40 and sTREM2 are associated with longitudinal volume and diffusivity changes in cognitively unimpaired individuals.

Neuroimage Clin 2019 Apr 1;23:101801. Epub 2019 Apr 1.

Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain; Alzheimer's Disease and Other Cognitive Disorders Unit, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain; Neurology Department, Hospital Clínic i Provincial de Barcelona, Barcelona, Spain; Universitat Pompeu Fabra, Spain; CIBER Fragilidad y Envejecimiento Saludable (CIBERFES), Madrid, Spain. Electronic address:

Cerebrospinal fluid (CSF) YKL40 and sTREM2 are astroglial and microglial activity biomarkers, respectively. We assessed whether CSF YKL40 and sTREM2 baseline levels are associated with longitudinal brain volume and diffusivity changes in cognitively unimpaired adults. Two brain MRI scans of 36 participants (57 to 78-years old, 12 male) were acquired in a 2-year interval. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.nicl.2019.101801DOI Listing
April 2019
1 Read

Plasma metabolomics in early Alzheimer's disease patients diagnosed with amyloid biomarker.

J Proteomics 2019 Apr 9;200:144-152. Epub 2019 Apr 9.

Neonatal Research Unit, Health Research Institute La Fe, Valencia, Spain. Electronic address:

An untargeted metabolomics study has been carried out using plasma samples from patients with Mild Cognitive Impairment due to Alzheimer's disease patients (MCI-AD, n = 29) and healthy people (n = 29)). They have been classified following the National Institute on Aging and Alzheimer's Association (NIA-AA) recommendations and cerebrospinal fluid biomarkers. The analytical method was based on liquid chromatography coupled to high resolution mass spectrometry. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jprot.2019.04.008DOI Listing
April 2019
4 Reads

A Comparative Evaluation of the KDSQ-C, AD8, and SMCQ as a Cognitive Screening Test to Be Used in National Medical Check-ups in Korea.

J Korean Med Sci 2019 Apr 15;34(14):e111. Epub 2019 Apr 15.

Department of Neurology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.

Background: Korea has a periodic general health check-up program that uses the Korean Dementia Screening Questionnaire-Cognition (KDSQ-C) as a cognitive dysfunction screening tool. The Alzheimer Disease 8 (AD8) and Subjective Memory Complaints Questionnaire (SMCQ) are also used in clinical practice. We compared the diagnostic ability of these screening questionnaires for cognitive impairment when completed by participants and their caregivers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3346/jkms.2019.34.e111DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6460109PMC
April 2019
1 Read

Full exploitation of high dimensionality in brain imaging: The JPND working group statement and findings.

Alzheimers Dement (Amst) 2019 Dec 30;11:286-290. Epub 2019 Mar 30.

Department of Epidemiology, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands.

Advances in technology enable increasing amounts of data collection from individuals for biomedical research. Such technologies, for example, in genetics and medical imaging, have also led to important scientific discoveries about health and disease. The combination of multiple types of high-throughput data for complex analyses, however, has been limited by analytical and logistic resources to handle high-dimensional data sets. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S23528729193001
Publisher Site
http://dx.doi.org/10.1016/j.dadm.2019.02.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6441785PMC
December 2019
1 Read

Locus coeruleus MRI contrast is reduced in Alzheimer's disease dementia and correlates with CSF Aβ levels.

Alzheimers Dement (Amst) 2019 Dec 27;11:281-285. Epub 2019 Mar 27.

German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany.

Introduction: This study aimed to assess how interindividual differences in locus coeruleus (LC) magnetic resonance imaging (MRI) contrast relate to cerebrospinal fluid (CSF) biomarkers of Alzheimer's disease (AD).

Methods: LC MRI contrast was quantified in 73 individuals from the DZNE Longitudinal Cognitive Impairment and Dementia Study (DELCODE) study comprising 25 healthy elderly adults and 21 individuals with subjective cognitive decline, 16 with mild cognitive impairment, and 11 participants with AD dementia using 3D T-weighted fast low-angle shot (FLASH) imaging (0.75 mm isotropic resolution). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.dadm.2019.02.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6439222PMC
December 2019
1 Read

Association study of rs3846662 with Alzheimer's disease in a population-based cohort: the Cache County Study.

Neurobiol Aging 2019 Mar 15. Epub 2019 Mar 15.

Department of Biology, Brigham Young University, Provo, UT, USA. Electronic address:

3-Hydroxy-3-methylglutaryl coenzyme A reductase is associated with monitoring cholesterol levels. The presence of the single-nucleotide polymorphism rs3846662 introduces alternative splicing at exon 13; the exclusion of this exon leads to a reduction in total cholesterol levels. Lower cholesterol levels are linked to a reduction in Alzheimer's disease (AD) risk. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neurobiolaging.2019.03.004DOI Listing
March 2019
4 Reads

Interval timing is disrupted in female 5xFAD mice: An indication of altered memory processes.

J Neurosci Res 2019 Apr 11. Epub 2019 Apr 11.

Timing and Decision Making Laboratory, Psychology Department, Koç University, Istanbul, Turkey.

Temporal information processing in the seconds-to-minutes range is disrupted in patients with Alzheimer's disease (AD). In this study, we investigated the timing behavior of the 5xFAD mouse model of AD in the peak interval (PI) procedure. Nine-month-old female mice were trained with sucrose solution reinforcement for their first response after a fixed-interval (FI) and tested in the inter-mixed non-reinforced PI trials that lasted longer than FI. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jnr.24418DOI Listing
April 2019
1 Read
2.594 Impact Factor

The Compounds -Crocin 4 and -Crocetin Modulate the Amyloidogenic Pathway and Tau Misprocessing in Alzheimer Disease Neuronal Cell Culture Models.

Front Neurosci 2019 26;13:249. Epub 2019 Mar 26.

Clinical Genomics and Pharmacogenomics Unit, 4th Department of Internal Medicine, Medical School, National and Kapodistrian University of Athens, Athens, Greece.

L. natural compounds have been extensively used in traditional medicine for thousands of years. Recent research evidence is now emerging in support of its therapeutic potential for different pathologies including neurodegenerative diseases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fnins.2019.00249DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6443833PMC
March 2019
1 Read

Do Nursing Home Residents With Dementia Receive Pain Interventions?

Am J Alzheimers Dis Other Demen 2019 May;34(3):193-198

3 New York State Department of Health, Bureau of Environmental & Occupational Epidemiology, Albany, NY, USA.

This study compares pain interventions received by nursing home residents with and without dementia. Secondary data analyses of cross-sectional data from 50,673 nursing home residents in New York State were collected by the Minimum Data Set 3.0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1533317519840506DOI Listing

Preliminary Results of a Trial of Atabecestat in Preclinical Alzheimer's Disease.

N Engl J Med 2019 04;380(15):1483-1485

Janssen Research and Development, Titusville, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1813435DOI Listing

Randomized Trial of Verubecestat for Prodromal Alzheimer's Disease.

N Engl J Med 2019 Apr;380(15):1408-1420

From Merck, Kenilworth, NJ (M.F.E., J.K., T.V., Y. Mukai, Y.Z., W.L., C.F., E.M., L.H.M., Y. Mo, C.S., D.M.); the University of Southern California, San Diego (P.S.A.); Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas (J.L.C.); Banner Alzheimer's Institute, Phoenix, AZ (P.N.T.); Gerontopole, INSERM Unité 1027, Alzheimer's Disease Research and Clinical Center, Toulouse University Hospital, Toulouse, France (B.V.); Yale University School of Medicine, New Haven, CT (C.H.D.); and the Research Center and Memory Clínic, Fundació Alzheimer Centre Educacional, Institut Català de Neurociènces Aplicades-Universitat Internacional de Catalunya, Barcelona, and the Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid - both in Spain (M.B.).

Background: Prodromal Alzheimer's disease offers an opportunity to test the effect of drugs that modify the deposition of amyloid in the brain before the onset of dementia. Verubecestat is an orally administered β-site amyloid precursor protein-cleaving enzyme 1 (BACE-1) inhibitor that blocks production of amyloid-beta (Aβ). The drug did not prevent clinical progression in a trial involving patients with mild-to-moderate dementia due to Alzheimer's disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1812840DOI Listing
April 2019
1 Read

Anosognosia of Financial Ability in Mild Cognitive Impairment.

Int J Geriatr Psychiatry 2019 Apr 9. Epub 2019 Apr 9.

Department of Neurology, University of Alabama at Birmingham, Birmingham, AL.

Objectives: Although financial ability has been well studied in mild cognitive impairment (MCI) and Alzheimer's disease (AD) using performance-based financial capacity assessment instruments, research is limited investigating everyday financial problems and declines in persons with AD and MCI, and the insight of people with MCI to recognize that financial capacity declines are occurring. To address this gap in the research, we investigated everyday financial activities and skills in a sample of older adults representing the dementia spectrum.

Methods: Participants were 186 older adults in three diagnostic classifications: cognitively healthy, MCI likely due to AD, and mild AD dementia. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1002/gps.5118
Publisher Site
http://dx.doi.org/10.1002/gps.5118DOI Listing
April 2019
2 Reads

Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study.

Alzheimers Dement 2019 Apr 6. Epub 2019 Apr 6.

Institute of Neuroscience and Physiology, The Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.

Introduction: Within-person trajectories of cerebrospinal fluid (CSF) biomarkers in Alzheimer's disease (AD) are not well defined.

Methods: We included 467 subjects from the BIOMARKAPD study with at least two serial CSF samples. Diagnoses were subjective cognitive decline (n = 75), mild cognitive impairment (n = 128), and AD dementia (n = 110), and a group of cognitively unimpaired subjects (n = 154) were also included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jalz.2019.01.015DOI Listing
April 2019
1 Read
12.407 Impact Factor

Risk of dementia in patients with end-stage renal disease under maintenance dialysis-a nationwide population-based study with consideration of competing risk of mortality.

Alzheimers Res Ther 2019 Apr 9;11(1):31. Epub 2019 Apr 9.

Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.

Background: Dementia is prevalent in the end-stage renal disease (ESRD) population. However, it is still not clarified whether ESRD is one of the etiology of dementia or its attributable effect on the cumulative risk of dementia. Meanwhile, the effect of competing risk of mortality should be taken into consideration when performing epidemiologic analyses among populations with high risk of mortality. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13195-019-0486-zDOI Listing
April 2019
2 Reads

Impact of Coexisting Overactive Bladder in Medicare Patients With Dementia on Clinical and Economic Outcomes.

Am J Alzheimers Dis Other Demen 2019 Apr 9:1533317519841164. Epub 2019 Apr 9.

3 Humana Inc, Cincinnati, OH, USA.

Background: Patients with dementia commonly suffer from symptoms of overactive bladder (OAB); however, limited research exists on the clinical impact of coexisting OAB among patients with dementia. As such, the objective of this study was to examine the impact of OAB on clinical outcomes, health-care resource use, and associated costs among patients with dementia.

Methods: We conducted a retrospective cohort analysis of patients with dementia using 3861 matched pairs of patients with and without OAB. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1533317519841164DOI Listing

Oral health care for patients with Alzheimer's disease: An update.

Spec Care Dentist 2019 Apr 9. Epub 2019 Apr 9.

Departments of Dentistry and Medicine, University of Rochester Medical Center, Rochester, New York.

Alzheimer's disease and related disorders (ADRD) are among the age-associated chronic conditions that are most challenging to health care systems around the globe, as patients with dementia require full-time, intensive care for multiple years. Oral health care is negatively impacted by cognitive decline, and consequently poor oral health is common among people with ADRD. Poor oral health status is linked with many undesirable consequences for the well-being of people with ADRD, from excruciating local pain to life-threatening conditions, as aspiration pneumonia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/scd.12375DOI Listing
April 2019
1 Read

Hemocompatibility of amyloid and/or brain targeted liposomes.

Future Med Chem 2019 Apr 9. Epub 2019 Apr 9.

Laboratory of Pharmaceutical Technology, Department of Pharmacy, University of Patras, Rio, 26510, Greece.

Targeted liposomes with different combinations of five ligands (for brain/amyloid targeting) were evaluated for hemocompatibility. Results reveal that all liposomes studied, caused minimum hemolysis; targeted liposomes slightly reduced blood coagulation time, but not significantly more than control liposomes; and compliment factors SC5b9 and iC3b increased when compared with the buffer, by most targeted liposomes. However, the specific amounts of both factors were similar with those induced by control liposomes. Read More

View Article

Download full-text PDF

Source
https://www.future-science.com/doi/10.4155/fmc-2018-0236
Publisher Site
http://dx.doi.org/10.4155/fmc-2018-0236DOI Listing
April 2019
4 Reads

Exploring the efficacy of natural products in alleviating Alzheimer's disease.

Neural Regen Res 2019 Aug;14(8):1321-1329

Department of Biology; Premedical Program; Center for Tissue Regeneration and Engineering at Dayton (TREND); The Integrative Science and Engineering Center; Center for Genomic Advocacy (TCGA), Indiana State University, Terre Haute, IN, USA.

Alzheimer's disease (hereafter AD) is a progressive neurodegenerative disorder that affects the central nervous system. There are multiple factors that cause AD, viz., accumulation of extracellular Amyloid-beta 42 plaques, intracellular hyper-phosphorylated Tau tangles, generation of reactive oxygen species due to mitochondrial dysfunction and genetic mutations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/1673-5374.253509DOI Listing
August 2019
1 Read

Modelling human pathology of traumatic brain injury in animal models.

J Intern Med 2019 Apr 8. Epub 2019 Apr 8.

Department of Neurobiology, Care Science and Society, Center for Alzheimer Research, Division of Neurogeriatrics, Karolinska Institutet, Solna, Sweden.

Traumatic brain injury (TBI) is caused by a head impact with a force exceeding regular exposure from normal body movement which the brain normally can accommodate. People affected include, but are not restricted to, sport athletes in American football, ice hockey, boxing as well as military personnel. Both single and repetitive exposures may affect the brain acutely and can lead to chronic neurodegenerative changes including chronic traumatic encephalopathy (CTE) associated with the development of dementia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/joim.12909DOI Listing
April 2019
1 Read

Neuroprotective potency of some spice herbs, a literature review.

J Tradit Complement Med 2019 Apr 30;9(2):98-105. Epub 2018 Apr 30.

Department of Physiology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

In recent years, growing attention has been given to traditional medicine. In traditional medicine a large number of plants have been used to cure neurodegenerative diseases such as Alzheimers disease (AD) and other memory related disorders. (), () and () were used traditionally for dietary, food additive, spice and various medicinal purposes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtcme.2018.01.002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6435951PMC
April 2019
1 Read

Nanowired delivery of cerebrolysin with neprilysin and p-Tau antibodies induces superior neuroprotection in Alzheimer's disease.

Prog Brain Res 2019 2;245:145-200. Epub 2019 Apr 2.

International Experimental Central Nervous System Injury & Repair (IECNSIR), Department of Surgical Sciences, Anesthesiology & Intensive Care Medicine, Uppsala University Hospital, Uppsala University, Uppsala, Sweden.

Alzheimer's disease (AD) is estimated to be afflicting over 55 millions of individual worldwide in 2018-19 for which no suitable clinical therapeutic measures have been developed so far. Thus, there is an urgent need to explore novel therapeutic strategies using nanodelivery of drugs and agents either alone or in combination for superior neuroprotection in AD and enhanced quality of life of the affected individuals. There are reports that AD is often associated with diminished neurotrophic factors and neprilysin together with enhancement of phosphorylated Tau (p-Tau) within the brain and in the cerebrospinal fluid (CSF). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/bs.pbr.2019.03.009DOI Listing
April 2019
1 Read

Is Brain-Derived Neurotrophic Factor a common link between neurodegenerative disorders and cancer?

Curr Alzheimer Res 2019 Apr 8. Epub 2019 Apr 8.

Neuroscience Research Lab, Department of Neurology, Postgraduate Institute of Medical Education and Research, Chandigarh. India.

Background: Cancer is a common disease caused by excessive proliferation of cells and neurodegenerative diseases are the disorders caused because of degeneration of neurons. Both can be considered as diseases caused by dysregulation of cell cycle events. Recent data suggests that there is a strong inverse association between cancer and neurodegenerative disorders, there is indirect evidence to postulate Brain-derived neurotrophic factor (BDNF) as apotential molecular link in this association. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1567205016666190408123947DOI Listing
April 2019
1 Read
3.889 Impact Factor

Impact of sex differences and gender specificity on behavioral characteristics and pathophysiology of neurodegenerative disorders.

Neurosci Biobehav Rev 2019 Apr 5. Epub 2019 Apr 5.

King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia. Electronic address:

The impact of neurodegenerative disorders in humans has multiple consequences because of the progressive decline in cognitive and physical performances. These disorders have diverse manifestations and are influenced by genetic and lifestyle factors, concurrent health conditions as well as un-modifiable predisposing risk factors, including gender and advanced age. Accumulating evidence indicates a gender-dependent natural bias of neurodegenerative diseases, such as, Alzheimer's disease, Parkinson's disease, Huntington's disease and multiple sclerosis, with the ratio of male to female prevalence as well as the severity of the disease differing significantly between the two sexes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neubiorev.2019.04.003DOI Listing
April 2019
1 Read

Users perspectives on medical assistance in dying for persons with dementia.

Int J Geriatr Psychiatry 2019 Apr 8. Epub 2019 Apr 8.

Alzheimer Disease Research Unit, McGill Center for Studies in Aging, Montreal, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/gps.5115DOI Listing

Cognitive Complaints in Nondemented Parkinson's Disease Patients and Their Close Contacts do not Predict Worse Cognitive Outcome.

Alzheimer Dis Assoc Disord 2019 Apr 4. Epub 2019 Apr 4.

Division of Neurology, Morton and Gloria Shulman Movement Disorders Center and the Edmond J Safra Program in Parkinson's disease, Toronto Western Hospital, University of Toronto.

Objectives: The main purpose of this study was to investigate 4 methods of eliciting subjective cognitive complaints (SCCs) in Parkinson's disease (PD) patients without dementia and determine the relationship between their SCC and cognitive performance.

Design: This study was a retrospective analysis of a prospective cohort study.

Setting: Six North American movement disorder clinics. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/WAD.0000000000000301DOI Listing
April 2019
2 Reads

A Computerized Continuous-Recognition Task for Measurement of Episodic Memory.

J Alzheimers Dis 2019 Apr 1. Epub 2019 Apr 1.

MemTrax, LLC, Redwood City, CA, USA.

Based on clinical observations of severe episodic memory (EM) impairment in dementia of Alzheimer's disease (AD), a brief, computerized EM test was developed for AD patient evaluation. A continuous recognition task (CRT) was chosen because of its extensive use in EM research. Initial experience with this computerized CRT (CCRT) showed patients were very engaged in the test, but AD patients had marked failure in recognizing repeated images. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/JAD-190167DOI Listing

Associations between Depression, Depressive Symptoms, and Incidence of Dementia in Latin America: A 10/66 Dementia Research Group Study.

J Alzheimers Dis 2019 Apr 1. Epub 2019 Apr 1.

Department of Health Service and Population Research, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.

Background: A growing body of evidence suggests that depression is related to dementia in older adults. Previous research has been done in high-income countries and there is a lack of studies in low- and middle income countries (LMICs).

Objective: To examine the relationship between depressive symptoms and incidence of dementia in a population-based study of older adults in Latin America. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/JAD-190148DOI Listing

Impact of Pre-Analytical Differences on Biomarkers in the ADNI and PPMI Studies: Implications in the Era of Classifying Disease Based on Biomarkers.

J Alzheimers Dis 2019 Apr 1. Epub 2019 Apr 1.

Department of Pathology, University of Washington School of Medicine, Seattle, WA, USA.

Background: Neurodegenerative diseases require characterization based on underlying biology using biochemical biomarkers. Mixed pathology complicates discovery of biomarkers and characterization of cohorts, but inclusion of greater numbers of patients with different, related diseases with frequently co-occurring pathology could allow better accuracy. Combining cohorts collected from different studies would be a more efficient use of resources than recruiting subjects from each population of interest for each study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/JAD-190069DOI Listing